








IN THE CLAIMS1-79. **(canceled)**80. **(currently amended)** A compound of formula **II**:**II**wherein, independently for each occurrence,

n is 0 to 10 inclusive;

R¹ is hydrogen or alkyl;R² is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, or aralkyl;Y is -C(R_b)_p-, -C(=O)- or -C(R_b)_pC(=O)-;X is hydrogen, -O-, -S-, -N(R_a)-, -N(R_a)-N(R_a)-, -C(=O)-, -C(=NR_a)-, -C(=NOH)-, -C(=S)- or -C(R_b)_p-;Z is absent, hydrogen, alkyl, haloalkyl, aryl, aralkyl, -CN, -OR_b, -(CH₂CH₂O)_pR_b, -C(=O)R_b, -C(=O)CH₂F, -C(=O)CHF₂, -C(=O)CF₃, -C(=O)CHN₂, -C(=O)OR_b,-C(=O)CH₂OC(=O)R_b, -C(=O)C(=C(R_b)₂)R_b,  or  ;

p is 0 to 20 inclusive;

R_a is hydrogen, alkyl, aryl or aralkyl;R_b is hydrogen, alkyl, haloalkyl, aryl or aralkyl; and== denotes a single bond, a *cis* double bond or a *trans* double bond;provided that the compound is not 13-*cis*-retinoic acid, all-*trans*-retinoic acid or N-(4-hydroxyphenyl)retinamide.81. **(currently amended)** The compound of claim 80, wherein said compound is a [[A]] compound of formula **IIa**, **IIb**, **IIc**, or **IId**:

**Ha****Hb****He****Hd**

wherein, independently for each occurrence,

n is 0 to 4 inclusive;

R¹ is hydrogen or alkyl;


R² is hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, aralkylenyl, aralkynyl, heteroaralkyl, heteroaralkylenyl, heteroaralkynyl, cyano, nitro, sulfhydryl, hydroxyl, sulfonyl, amino, acylamino, amido, alkylthio, carboxyl, carbamoyl, alkoxyl, sulfonate, sulfate, sulfonamido, sulfamoyl, sulfonyl, and sulfoxido;

R⁴ is absent, hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, aralkylenyl, aralkynyl, heteroaralkyl, heteroaralkylenyl, heteroaralkynyl, cyano, nitro, sulfhydryl, hydroxyl, sulfonyl, amino, acylamino, amido, alkylthio, carboxyl, carbamoyl, alkoxyl, sulfonate, sulfate, sulfonamido, sulfamoyl, sulfonyl, and sulfoxido;

Y is -C(=O)- or -C(R_b)₂-;

X is hydrogen, -O-, -S-, -N(R_a)-, -N(R_a)-N(R_a)-, -C(=O)-, -C(=NR_a)-, -C(=NOH)-, -C(=S)- or -C(R_b)₂-;

Z is absent, hydrogen, alkyl, haloalkyl, aryl, aralkyl, -CN, -OR_b, -C(=O)R_b, -C(=O)CH₂F, -C(=O)CHF₂, -C(=O)CF₃, -C(=O)CHN₂, -C(=O)CH₂OC(=O)R_b, -C(=O)OR_b,



R_a is hydrogen, alkyl, aryl or aralkyl;

R_b is hydrogen, alkyl, haloalkyl, aryl or aralkyl; and

== denotes a single bond, a *cis* double bond or a *trans* double bond.

82. (canceled)

83. (canceled)

84. (currently amended) The compound of claim 81 ~~any one of claims 81-83~~, wherein R¹ is hydrogen or methyl.

85. (canceled)

86. (canceled)

87. (currently amended) The compound of claim 81 ~~any one of claims 81-86~~, wherein Y is -CH₂-

88. (currently amended) The compound of claim 81 ~~any one of claims 81-87~~, wherein X is -O-.

89. (currently amended) The compound of claim 81 ~~any one of claims 81-87~~, wherein X is -NH-.


90. (canceled)

91. (canceled)


92. (currently amended) The compound of claim 81 ~~any one of claims 81-91~~, wherein Z is alkyl.

93. (canceled)



94. (currently amended) The compound of claim 80, wherein said compound is a [[A]] compound of formula ~~He~~, ~~Hf~~, ~~Hg~~, or ~~Ih~~:



He



Hf

**Hg****IIh**

wherein, independently for each occurrence,


n is 0 to 4 inclusive;

R¹ is hydrogen or alkyl;

R³ is ~~hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, aralkenyl, aralkynyl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, cyano, nitro, sulfhydryl, hydroxyl, sulfonyl, amino, acylamino, amido, alkylthio, carboxyl, carbamoyl, alkoxy, sulfonate, sulfate, sulfonamido, sulfamoyl, sulfonyl, and sulfoxido;~~

X is hydrogen, -O-, -S-, -N(R_a)-, -N(R_a)-N(R_a)-, -C(=O)-, -C(=NR_a)-, -C(=NOH)-, -C(=S)- or -C(R_b)₂-;

Z is absent, hydrogen, alkyl, haloalkyl, aryl, aralkyl, -CN, -OR_b, -C(=O)R_b, -C(=O)CH₂F, -C(=O)CHF₂, -C(=O)CF₃, -C(=O)CHN₂, -C(=O)CH₂OC(=O)R_b, -C(=O)OR_b,



R_a is hydrogen, alkyl, aryl or aralkyl; and

R_b is hydrogen, alkyl, haloalkyl, aryl or aralkyl.


95. **(canceled)**

96. **(canceled)**


97. **(currently amended)** The compound of claim 96 ~~any one of claims 94-96~~, wherein R¹ is hydrogen or methyl.

98-109. (canceled)

110. (currently amended) The compound of claim 80, wherein said compound is a [[A]]



111. (currently amended) A compound of formula **III**:



III

wherein, independently for each occurrence,

n is 0 to 10 inclusive;

R¹ is hydrogen or alkyl;

R² is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, or aralkyl;

Y is -CR_b(OR_b)-, -CR_b(N(R_a)₂)-, -C(R_b)_p-, -C(=O)- or -C(R_b)_pC(=O)-;

X is -O-, -S-, -N(R_a)-, -C(=O)-, or -C(R_b)_p-;

Z is hydrogen, alkyl, haloalkyl, aryl, aralkyl, -OR_b, -N(R_b)₂, -(CH₂CH₂O)_pR_b, -C(=O)R_b, -C(=NR_a)R_b, -C(=NOR_b)R_b, -C(OR_b)(R_b)₂, -C(N(R_a)₂)(R_b)₂ or -(CH₂CH₂O)_pR_b;

p is 0 to 20 inclusive;





R_a is hydrogen, alkyl, aryl or aralkyl;

R_b is hydrogen, alkyl, haloalkyl, aryl or aralkyl; and

== denotes a single bond or a *trans* double bond;

provided that the compound is not 13-*cis*-retinoic acid, all-*trans*-retinoic acid or N-(4-hydroxyphenyl)retinamide.

112. (currently amended) The compound of claim 111, wherein said compound is a [[A]]
compound of formula **IIIa**, ~~**IIIb**~~, ~~**IIIc**~~ or **IIId**:

**IIIa****IIIb****IIIc****IIId**

wherein, independently for each occurrence,

n is 0 to 4 inclusive;

R¹ is hydrogen or alkyl;

R⁴ is absent, hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, aralkylenyl, aralkynyl, heteroaralkyl, heteroaralkylenyl, heteroaralkynyl, cyano, nitro, sulfhydryl, hydroxyl, sulfonyl, amino, acylamino, amido, alkylthio, carboxyl, carbamoyl, alkoxy, sulfonate, sulfate, sulfonamido, sulfamoyl, sulfonyl, and sulfoxido;

Y is -C(=O)-, -CR_b(OR_b)-, -CR_b(N(R_a)₂)- or -C(R_b)₂-;

X is -O-, -S-, -N(R_a)-, -C(=O)-, or -C(R_b)₂-;

Z is hydrogen, alkyl, haloalkyl, aryl, aralkyl, -OR_b, -N(R_b)₂, -C(=O)R_b, -C(=NR_a)R_b, -C(=NOH)R_b, -C(OR_b)(R_b)₂, -C(N(R_a)₂)(R_b)₂ or -(CH₂CH₂O)_pR_b;

R_a is hydrogen, alkyl, aryl or aralkyl;

R_b is hydrogen, alkyl, haloalkyl, aryl or aralkyl;





p is 0 to 10 inclusive; and

== denotes a single bond or a *trans* double bond;

provided that the compound is not 13-*cis*-retinoic acid, all-*trans*-retinoic acid or N-(4-hydroxyphenyl)retinamide.

113. **(canceled)**

114. **(canceled)**
115. **(currently amended)** The compound of claim 112 ~~any one of claims 112-114~~, wherein R^1 is hydrogen or methyl.
116. **(canceled)**
117. **(canceled)**
118. **(currently amended)** The compound of claim 112 ~~any one of claims 112-117~~, wherein X is -O-.
119. **(currently amended)** The compound of claim 112 ~~any one of claims 112-117~~, wherein X is -NH-.
120. **(currently amended)** The compound of claim 112 ~~any one of claims 112-117~~, wherein X is -C(R_b)₂-.
121. **(canceled)**
122. **(currently amended)** The compound of claim 112 ~~any one of claims 112-121~~, wherein Z is alkyl.
123. **(canceled)**
124. **(currently amended)** The compound of claim 111, wherein said compound is a [[A] compound of formula ~~IIIe, IIIf, IIIg, or IIIh~~:

**IIIe****IIIf****IIIg****IIIh**

wherein, independently for each occurrence,

n is 0 to 4 inclusive;

R¹ is hydrogen or alkyl;

X is -O-, -S-, -N(R_a)-, -C(=O)-, or -C(R_b)₂-;

Z is hydrogen, alkyl, haloalkyl, aryl, aralkyl, -OR_b, -N(R_b)₂, -C(=O)R_b, -C(=NR_a)R_b, -C(=NOH)R_b, -C(OR_b)(R_b)₂, -C(N(R_a)₂)(R_b)₂ or -(CH₂CH₂O)_pR_b;

R_a is hydrogen, alkyl, aryl or aralkyl;

R_b is hydrogen, alkyl, haloalkyl, aryl or aralkyl; and

p is 0 to 10 inclusive.


125. **(canceled)**

126. **(canceled)**

127. **(currently amended)** The compound of claim 124 ~~any one of claims 124-126~~, wherein R¹ is hydrogen or methyl.

128-135. **(canceled)**

136. **(original)** A compound of formula **IV**:



IV

wherein, independently for each occurrence,

n is 1, 2, 3 or 4;

Y is -C(R_b)₂- or -C(=O)-;


X is -O-, -NR_a-, -C(R_b)₂- or -C(=O)-;


Z is -C(=O)R_b, -OR_b, -N(R_b)₂, alkyl or haloalkyl;

R_a is hydrogen, alkyl, haloalkyl, aryl or aralkyl; and

R_b is hydrogen, alkyl, haloalkyl, aryl or aralkyl.


137. **(original)** The compound of claim 136, wherein Y is -CH₂-.
138. **(currently amended)** The compound of claim 136 ~~or claim 137~~, wherein X is -O-.
139. **(canceled)**
140. **(currently amended)** The compound of claim 136 ~~any one of claims 136-138~~, wherein Z is alkyl.
141. **(canceled)**
142. **(original)** The compound of claim 136, wherein Y is -CH₂-; X is -O-; and Z is alkyl.
143. **(canceled)**
144. **(canceled)**
145. **(currently amended)** ~~A compound having a structure represented by~~ The compound of claim 136, wherein said compound is selected from the group consisting of





146-158. (canceled)

159. (original) A compound of formula V:



wherein, independently for each occurrence,

n is 1, 2 or 3;

Y is $-\text{C}(\text{R}_b)_2-$, $-\text{C}(=\text{O})-$ or $-\text{CH}(\text{OH})-$;

X is -O-, -NR_a- or -C(R_b)₂-;

Z is -C(=O)R_b, hydrogen, -(CH₂CH₂O)_pR_b, alkyl or haloalkyl;

R_a is hydrogen, alkyl, haloalkyl, aryl or aralkyl;

R_b is hydrogen, alkyl, haloalkyl, aryl or aralkyl; and

p is 1 to 10 inclusive;

provided that the compound is not 13-*cis*-retinoic acid, all-*trans*-retinoic acid or N-(4-hydroxyphenyl)retinamide.

160. **(canceled)**

161. **(original)** The compound of claim 159, wherein Y is -C(=O)-.






162. **(canceled)**


163. **(canceled)**


164. **(currently amended)** The compound of claim 159 ~~any one of claims 159-162~~, wherein X is -NR_a-

165-168. **(canceled)**

169. **(currently amended)** ~~A compound having a structure represented by~~ The compound of claim 159, wherein said compound is selected from the group consisting of








170-256. (canceled)

257. (currently amended) A formulation comprising a first compound and a second compound, wherein said first compound and said second compound are independently selected from the group consisting of:

a compound of formula **IIA**:

**IIA**

wherein, independently for each occurrence,

n is 0 to 10 inclusive;


R¹ is hydrogen or alkyl;

R² is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, or aralkyl;

Y¹ is -C(R_b)_p-, -C(=O)- or -C(R_b)_pC(=O)-;

X¹ is hydrogen, -O-, -S-, -N(R_a)-, -N(R_a)-N(R_a)-, -C(=O)-, -C(=NR_a)-,
-C(=NOH)-, -C(=S)- or -C(R_b)_p-;

Z¹ is absent, hydrogen, alkyl, haloalkyl, aryl, aralkyl, -CN, -OR_b,
-(CH₂CH₂O)_pR_b, -C(=O)R_b, -C(=O)CH₂F, -C(=O)CHF₂, -C(=O)CF₃,
-C(=O)CHN₂, -C(=O)OR_b, -C(=O)CH₂OC(=O)R_b, -C(=O)C(=C(R_b)₂)R_b,




p is 0 to 20 inclusive;

R_a is hydrogen, alkyl, aryl or aralkyl;

R_b is hydrogen, alkyl, haloalkyl, aryl or aralkyl; and

== denotes a single bond, a *cis* double bond or a *trans* double bond;

a compound of formula **IIIA**:

**IIIA**

wherein, independently for each occurrence,

m is 0 to 10 inclusive;

R³ is hydrogen or alkyl;

R⁴ is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, or aralkyl;

Y² is -CR_d(OR_d)-, -CR_d(N(R_c)₂)-, -C(R_d)_p-, -C(=O)- or -C(R_d)_pC(=O)-;

X² is -O-, -S-, -N(R_c)-, -C(=O)-, or -C(R_d)_p-;

Z² is hydrogen, alkyl, haloalkyl, aryl, aralkyl, -OR_d, -N(R_d)₂, -(CH₂CH₂O)_pR_d,
-C(=O)R_d, -C(=NR_c)R_d, -C(=NOR_d)R_d, -C(OR_d)(R_d)₂, -C(N(R_c)₂)(R_d)₂ or
-(CH₂CH₂O)_pR_d;


p is 0 to 20 inclusive;

R_c is hydrogen, alkyl, aryl or aralkyl;

R_d is hydrogen, alkyl, haloalkyl, aryl or aralkyl; and

== denotes a single bond or a *trans* double bond;

a compound of formula **IVA**:



IVA

wherein, independently for each occurrence,

q is 1, 2, 3 or 4;

Y³ is -C(R_f)₂- or -C(=O)-;


X³ is -O-, -NR_e-, -C(R_f)₂- or -C(=O)-;

Z³ is -C(=O)R_f, -OR_f, -N(R_f)₂, alkyl or haloalkyl;

R_e is hydrogen, alkyl, haloalkyl, aryl or aralkyl; and

R_f is hydrogen, alkyl, haloalkyl, aryl or aralkyl;

or a compound of formula **VA**:

**VA**

wherein, independently for each occurrence,

r is 1, 2 or 3;

Y⁴ is -C(R_h)₂-, -C(=O)- or -CH(OH)-;

X⁴ is -O-, -NR_g- or -C(R_h)₂-;

Z⁴ is -C(=O)R_h, hydrogen, -(CH₂CH₂O)_pR_h, alkyl or haloalkyl;

R_g is hydrogen, alkyl, haloalkyl, aryl or aralkyl;

R_h is hydrogen, alkyl, haloalkyl, aryl or aralkyl; and


p is 1 to 10 inclusive;

provided that the defined by any one of claims 51-257, and a second compound[[,]] is different from the first compound, also as defined by any one of claims 51-257.

258-264. **(canceled)**

265. **(new)** A method for treating or preventing an ophthalmologic disorder in a subject comprising administering to a subject a pharmaceutically acceptable amount of a compound selected from the group consisting of:

a compound of formula **IIA**:

**IIA**

wherein, independently for each occurrence,

n is 0 to 10 inclusive;


R¹ is hydrogen or alkyl;

R^2 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, or aralkyl;

Y^1 is $-C(R_b)_p-$, $-C(=O)-$ or $-C(R_b)_pC(=O)-$;

X^1 is hydrogen, $-O-$, $-S-$, $-N(R_a)-$, $-N(R_a)-N(R_a)-$, $-C(=O)-$, $-C(=NR_a)-$, $-C(=NOH)-$, $-C(=S)-$ or $-C(R_b)_p-$;

Z^1 is absent, hydrogen, alkyl, haloalkyl, aryl, aralkyl, $-CN$, $-OR_b$, $-(CH_2CH_2O)_pR_b$, $-C(=O)R_b$, $-C(=O)CH_2F$, $-C(=O)CHF_2$, $-C(=O)CF_3$, $-C(=O)CHN_2$, $-C(=O)OR_b$, $-C(=O)CH_2OC(=O)R_b$, $-C(=O)C(=C(R_b)_2)R_b$,




p is 0 to 20 inclusive;

R_a is hydrogen, alkyl, aryl or aralkyl;

R_b is hydrogen, alkyl, haloalkyl, aryl or aralkyl; and

$==$ denotes a single bond, a *cis* double bond or a *trans* double bond;

a compound of formula **IIIA**:



IIIA

wherein, independently for each occurrence,

m is 0 to 10 inclusive;

R^3 is hydrogen or alkyl;

R^4 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, or aralkyl;

Y^2 is $-CR_d(OR_d)-$, $-CR_d(N(R_c)_2)-$, $-C(R_d)_p-$, $-C(=O)-$ or $-C(R_d)_pC(=O)-$;

X^2 is $-O-$, $-S-$, $-N(R_c)-$, $-C(=O)-$, or $-C(R_d)_p-$;

Z^2 is hydrogen, alkyl, haloalkyl, aryl, aralkyl, $-OR_d$, $-N(R_d)_2$, $-(CH_2CH_2O)_pR_d$, $-C(=O)R_d$, $-C(=NR_c)R_d$, $-C(=NOR_d)R_d$, $-C(OR_d)(R_d)_2$, $-C(N(R_c)_2)(R_d)_2$ or $-(CH_2CH_2O)_pR_d$;


p is 0 to 20 inclusive;

R_c is hydrogen, alkyl, aryl or aralkyl;

R_d is hydrogen, alkyl, haloalkyl, aryl or aralkyl; and

\equiv denotes a single bond or a *trans* double bond;

a compound of formula **IVA**:



IVA

wherein, independently for each occurrence,

q is 1, 2, 3 or 4;

Y^3 is $-C(R_f)_2-$ or $-C(=O)-$;


X^3 is $-O-$, $-NR_e-$, $-C(R_f)_2-$ or $-C(=O)-$;

Z^3 is $-C(=O)R_f$, $-OR_f$, $-N(R_f)_2$, alkyl or haloalkyl;

R_e is hydrogen, alkyl, haloalkyl, aryl or aralkyl; and

R_f is hydrogen, alkyl, haloalkyl, aryl or aralkyl;

or a compound of formula **VA**:



VA

wherein, independently for each occurrence,

r is 1, 2 or 3;

Y^4 is $-C(R_h)_2-$, $-C(=O)-$ or $-CH(OH)-$;

X^4 is $-O-$, $-NR_g-$ or $-C(R_h)_2-$;

Z^4 is $-C(=O)R_h$, hydrogen, $-(CH_2CH_2O)_pR_h$, alkyl or haloalkyl;

R_g is hydrogen, alkyl, haloalkyl, aryl or aralkyl;

R_h is hydrogen, alkyl, haloalkyl, aryl or aralkyl; and

p is 1 to 10 inclusive.

- 266. **(new)** The method of claim 265, wherein the ophthalmologic disorder is a macular degeneration.
- 267. **(new)** The method of claim 265, wherein the ophthalmologic disorder is Stargardt's disease.
- 268. **(new)** The method of claim 265, wherein the ophthalmologic disorder is lipofuscin accumulation.
- 269. **(new)** The method of claim 265, wherein a second drug different from the first drug is used in the preparation of the medicament.
- 270. **(new)** The method of claim 269, wherein the second drug inhibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.
- 271. **(new)** A method of treating or preventing an ophthalmologic disorder in a subject comprising administering to a subject a pharmaceutically acceptable amount of fenretinide or a pharmaceutically acceptable salt thereof.
- 272. **(new)** The method of claim 271, wherein fenretinide inhibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.
- 273. **(new)** The method of claim 271, wherein the ophthalmologic disorder is macular degeneration.
- 274. **(new)** The method of claim 271, wherein the ophthalmologic disorder is Stargardt's disease.

275. **(new)** The method of claim 271, wherein the ophthalmologic disorder is lipofuscin accumulation.
276. **(new)** The method of claim 271, wherein fenretinide increases the rate at which 11-*cis*-retinal is isomerized to all-*trans*-retinal; inhibits, antagonizes, or short-circuits the visual cycle in the retinal pigment epithelium; inhibits at least one of lecithin retinol acyl transferase, isomerohydrolase, and 11-*cis*-retinol dehydrogenase, or inhibits binding to RPE65.
277. **(new)** The method of claim 271, wherein a second drug different from the first drug is used in the preparation of the medicament.
278. **(new)** The method of claim 277, wherein the second drug inhibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.
279. **(new)** The method of claim 277, wherein both fenretinide and the second drug inhibit or antagonize a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.